{
    "symbol": "SILK",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-28 20:22:11",
    "content": " All forward-looking statements including without limitation, those relating to our operating trends and future financial performance, expense management, expectations for hiring and growth in our organization and our business, physician training and adoption, market opportunity and penetration, commercial and international expansion, regulatory approvals, reimbursement, competition and product development are based upon our current estimates and various assumptions. 2022 closes the books on a remarkable year at Silk Road, we achieved a total revenue of $138.6 million, supported by over 19,500 procedures representing 37% and 41% year-over-year growth respectively. We are pleased to initiate guidance of $176 million to $184 million in full-year 2023 revenue, reflecting roughly 25,000 TCAR procedures at the midpoint of the range. As Erica mentioned, we expect full-year revenue to be in the range of $176 million to $184 million reflecting revenue growth of 27% to 33% over 2022 based on roughly 25,000 TCAR procedures at the midpoint of the range. I would like to reiterate that 2023 will be a year of growth and leverage for Silk Road carried by our team who has focused on building and scaling our platform for the last several years to put TCAR in the hands of more physicians, and benefit as many patients as possible."
}